Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
This is the first NDA acceptance for BTK inhibitor orelabrutinib in autoimmune diseases. No BTK inhibitors have been approved in China for ITP.
-
- Phase 1 trial designed to evaluate the safety, tolerability, and pharmacokinetic properties of ICP-054 (ZB021) in healthy volunteers - Phase 1 SAD and MAD data expected by year-end 2026 BEIJING,...
-
ICP-488 is expected to provide a novel therapeutic option for patients. There are no approved targeted therapies for Sjögren's syndrome globally.